This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MARTINA, V. Articles by CAMANNI, F. Search for Related Content PubMed PubMed Citation Articles by MARTINA, V. Articles by CAMANNI, F.

Chronic Treatment With Pirenzepine Decreases Growth Hormone Secretion in Insulin-Dependent Diabetes Mellitus

Department of Biomedicine, Division of Endocrinology, University of Turin Turin, Italy

Address all correspondence and requests for reprints to: Prof. F. Camanni, Divisione di Endocrinologia, Ospedale Molinette, C.so Polonia 14, 10126 Torino, Italy.

We and others previously reported that nocturnal GH secretion in patients with insulin-dependent diabetes mellitus is blunted by acute cholinergic muscarinic blockade with pirenzepine. In this study, we investigated whether this inhibitory effect on GH secretion persists during chronic pirenzepine administration, and if pirenzepine administration affects glycemic control. Nocturnal GH secretion was studied from 2300–0800 h before and after one month of pirenzepine administration (100 mg/day, orally, given at 2300 h) in 13 diabetic patients receiving their usual insulin treatment. GH secretion (GH area under curve) was blunted after pirenzepine administration [mean, 877 ± 215 (±SE) vs. 1407 ± 311 µg/L·min; P < 0.002]. During pirenzepine administration, hemoglobin Alc significantly decreased (P < 0.02), and 4 of the 13 patients had lower daily insulin requirements (5–23 U/day), but there was no significant change for the group as a whole. These results indicate that the inhibitory effect of pirenzepine on GH secretion persists when pirenzepine is given chronically and that pirenzepine seems to improve the metabolic control of the patients.

Received May 16, 1988.

This article has been cited by other articles:

				T. Saukkonen, F. Shojaee-Moradie, R. M. Williams, R. Amin, K. C. Yuen, A. Watts, C. L. Acerini, A. M. Umpleby, and D. B. Dunger Effects of Recombinant Human IGF-I/IGF-Binding Protein-3 Complex on Glucose and Glycerol Metabolism in Type 1 Diabetes. Diabetes, August 1, 2006; 55(8): 2365 - 2370. [Abstract] [Full Text] [PDF]

				T. Saukkonen, R. Amin, R. M. Williams, C. Fox, K. C. Yuen, M. A. White, A. M. Umpleby, C. L. Acerini, and D. B. Dunger Dose-Dependent Effects of Recombinant Human Insulin-Like Growth Factor (IGF)-I/IGF Binding Protein-3 Complex on Overnight Growth Hormone Secretion and Insulin Sensitivity in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4634 - 4641. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]